Notice on Convening the 2024 Annual General Meeting
Filed with SSE · · 8 pages · Chinese
Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. on 6ix
Earlier from Shanghai Fudan Zhangjiang Bio Pharmaceutical
- Announcement on Attending the 2024 SSE STAR Market Innovative Drug Industry Collective Performance Briefing
- Announcement on the Special Report on Deposit and Actual Use of Raised Funds in 2024
- Announcement on Convening Annual Performance Briefing 2024
- Announcement on Voluntary Disclosure Regarding the Completion of First Subject Enrollment in Confirmatory Clinical Trial for the Visualization of Bladder Cancer Surgery Using Aminolevulinic Acid Hydrochloride Granules
- Announcement on Expiration of Plan of Shareholding Reduction by Shareholders with Over 5% Shares and Results of Shareholding Reduction
Later from Shanghai Fudan Zhangjiang Bio Pharmaceutical
- Announcement on Drug Price Adjustment
- Announcement on Voluntary Disclosure of Obtaining Notice on Acceptance of Drug Clinical Trial Application for FZ-P001 Sodium for Injection for Intraoperative Visualization of Malignant Lesions in Cancer
- Announcement on Share Reduction Plan for Shareholders with Over 5% Shares
- Announcement on Resolution of the 2024 Annual General Meeting
- Announcement on Adjusting Member of Nomination Committee of the Board of Directors
Follow Shanghai Fudan Zhangjiang Bio Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai Fudan Zhangjiang Bio Pharmaceutical